The goal of this program is to train MD and PhD postdoctoral fellows in biomedical research as it applies to Blood Coagulation and Vascular Biology. We offer a multi-disciplinary program that consists of didactic instruction, seminars and supervised research. Important elements of the curriculum are supervision by faculty advisors, formal course work, interactions between trainee and the faculty, and interactions between the trainee and peers. Dr. Robert Flaumenhaft is the Program Director and Drs. Bruce Furie and Kenneth Bauer are the Associate Program Directors. Faculty of the program, largely members of the Department of Medicine at Beth Israel Deaconess Medical Center and Harvard Medical School, share a scientific interest in blood coagulation and vascular biology. MD trainees are selected from 350 to 425 applicants each year. Only those applicants with an explicit commitment to a career in academic medicine are selected. This training plan is integrated into the hematology training program. MD trainees choose between two tracks. The Physician-Scientist Track consists of a minimum of two years of supervised bench research and didactic instruction after completion of the major portion of hospital-funded clinical subspecialty training. The Clinical Investigator Track prepares participants for a career in clinical investigation in the areas of blood coagulation and vascular biology. We also receive approximately 300 applications per year from candidates with a PhD degree or physicians applying solely for research training. The design of the program takes into account (a) the need for physicians to acquire knowledge of advances in molecular and cell biology; (b) the need for an extended training experience to allow fellows to develop sophistication in modern biomedical research; (c) the need for PhD scientists to understand the pathobiology of the vascular system. This grant, funded for the past 18 years, is a continuation of T32 HL07437, which had been active at Tufts Medical Center for 20 years. This training program has proved exceptionally successful, with over 50% of our trainees obtaining Faculty positions at academic centers, 38% pursuing careers in the biotechnology sector, 5% working in alterative scientific academic roles (e.g., senior editor) and less than 5% in private practice. This Program has produced leaders in the fields of blood coagulation and vascular biology and has had important impact in sustaining basic research in the field of hemostasis and thrombosis.

Public Health Relevance

Research in hemostasis, thrombosis, and vascular biology addresses fundamental mechanisms underlying bleeding and thrombotic disorders, which as a group account for more than half of all morbity and mortality among U.S. citizens. This Program in Blood Coagulation and Vascular Biology will train the next generation of scientists to study problems related to hemostasis, thrombosis, and vascular biology.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Institutional National Research Service Award (T32)
Project #
5T32HL007917-22
Application #
9913565
Study Section
NHLBI Institutional Training Mechanism Review Committee (NITM)
Program Officer
Mondoro, Traci
Project Start
1999-07-01
Project End
2024-08-31
Budget Start
2020-09-01
Budget End
2021-08-31
Support Year
22
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
02215
Sharda, Anish; Furie, Bruce (2018) Regulatory role of thiol isomerases in thrombus formation. Expert Rev Hematol 11:437-448
Higgins, Sarah J; De Ceunynck, Karen; Kellum, John A et al. (2018) Tie2 protects the vasculature against thrombus formation in systemic inflammation. J Clin Invest 128:1471-1484
De Ceunynck, Karen; Peters, Christian G; Jain, Abhishek et al. (2018) PAR1 agonists stimulate APC-like endothelial cytoprotection and confer resistance to thromboinflammatory injury. Proc Natl Acad Sci U S A 115:E982-E991
Jain, A; Barrile, R; van der Meer, A D et al. (2018) Primary Human Lung Alveolus-on-a-chip Model of Intravascular Thrombosis for Assessment of Therapeutics. Clin Pharmacol Ther 103:332-340
Stopa, Jack D; Zwicker, Jeffrey I (2018) The intersection of protein disulfide isomerase and cancer associated thrombosis. Thromb Res 164 Suppl 1:S130-S135
Stopa, Jack D; Baker, Katherine M; Grover, Steven P et al. (2017) Kinetic-based trapping by intervening sequence variants of the active sites of protein-disulfide isomerase identifies platelet protein substrates. J Biol Chem 292:9063-9074
Flaumenhaft, Robert; De Ceunynck, Karen (2017) Targeting PAR1: Now What? Trends Pharmacol Sci 38:701-716
Bowley, Sheryl R; Fang, Chao; Merrill-Skoloff, Glenn et al. (2017) Protein disulfide isomerase secretion following vascular injury initiates a regulatory pathway for thrombus formation. Nat Commun 8:14151
Jain, Abhishek; Graveline, Amanda; Waterhouse, Anna et al. (2016) A shear gradient-activated microfluidic device for automated monitoring of whole blood haemostasis and platelet function. Nat Commun 7:10176
Flaumenhaft, Robert; Furie, Bruce (2016) Vascular thiol isomerases. Blood 128:893-901

Showing the most recent 10 out of 34 publications